Related Experiment Video
Updated: Jul 11, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
A multimodal deep learning classifier for prediction of HER2-low expression in triple-negative breast cancer
Junfei Fang1, Tianle Hong1, Yulan Tong2
1The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Background:
Triple-negative breast cancer (TNBC) is an aggressive molecular subtype. With the new definition of HER2-low status and the availability of anti-HER2 drug conjugates, the drug regimens for HER2-low patients in TNBC could be individually tailored.
Methods:
A total of 122 patients with 122 pathologically confirmed TNBCs was retrospectively investigated from 2017 to 2022. Breast US and multiparametric MRI (T2WI, DWI and DCE-MRI) were collected and analyzed. To address data scarcity, a few-shot deep learning framework (FADNET) was developed and evaluated under simulated data-constrained conditions. The model used a frozen ResNet34 backbone trained via contrastive learning and soft k-means for classification. We compared pre-treatment imaging-only models (single modalities and multimodal fusion) against a hybrid model (CLI-FADNET) that incorporated imaging and a postoperative clinical variable for post-surgical assessment.
Results:
Of 122 TNBC cases, 13 (11%) patients experienced postoperative recurrence. Most clinical characteristics showed no significant differences between HER2-zero and HER2-low groups except for postoperative lymph node metastasis (≥ 4 positive nodes) (P = 0.004). Pre-treatment models based on a single imaging modality achieved AUCs ranging from 0.764 to 0.806, while the multimodal imaging fusion model improved the AUC to 0.877. The CLI-FADNET model, integrated with the postoperative clinical variable, further increased the AUC to 0.884.
Conclusion:
This study validates the FADNET few-shot learning framework for classifying HER2 status under data-constrained conditions. While the imaging-only models offer pre-treatment evaluation, the CLI-FADNET hybrid model serves as a comprehensive post-surgical assessment tool. Rather than presenting a fully deployable clinical model, this methodological validation demonstrates the potential of few-shot learning in rare tumor subtypes, establishing a foundation for future large-scale external validation.